Florence Joly
Inserm(FR)Inserm(FR)Université Paris Cité(FR)Hôpital Beaujon(FR)La Ligue Contre le Cancer(FR)Assistance Publique – Hôpitaux de Paris(FR)Centre François Baclesse(LU)Normandie Université(FR)Laboratoire de Physique Corpusculaire de Caen(FR)Centre Hospitalier Universitaire de Caen(FR)Centre Hospitalier Universitaire de Caen Normandie(FR)Centre François Baclesse(FR)Cancers et Préventions(FR)Neuropsychologie et Imagerie de la Mémoire HumaineUniversité de Rouen Normandie(FR)Université de Caen Normandie(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Cancer-related cognitive impairment studies, Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, Cancer survivorship and care
Most-Cited Works
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial(2015)856 cited
- → Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis(2011)735 cited
- → Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial(2013)732 cited
- →